Drug
Td-8954 clinical trials
Also written TAK-954 and TD-8954.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Takeda (6) · Millennium Pharmaceuticals, Inc. (3) · Theravance Biopharma (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses td-8954 is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After SurgeryCompletedPhase 2TakedaNCT03827655Written as TAK-954
- Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis ParticipantsCompletedPhase 2TakedaNCT03281577Written as TAK-954
- A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954CompletedPhase 1TakedaNCT03296787Written as TAK-954
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03870555Written as TAK-954
- A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding IntoleranceCompletedPhase 1/2TakedaNCT01953081Written as TD-8954
- A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954CompletedPhase 1TakedaNCT03277274Written as TAK-954
- TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)TerminatedPhase 2Millennium Pharmaceuticals, Inc.NCT03477903Written as TAK-954
- A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03500224Written as [14C]-TAK-954
- A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult ParticipantsCompletedPhase 1TakedaNCT03173170Written as TAK-954
- A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy SubjectsTerminatedPhase 1Theravance BiopharmaNCT01644240Written as TD-8954
Codes
What other systems call td-8954 · ClinicalTrials.gg INT006293
- UNII (FDA) 35F0Y2W16QFELCISETRAGConfirmed FDA, Wikidata
- Wikidata Q27088952td-8954Confirmed FDA, Wikidata
- DrugBank DB12725One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 35F0Y2W16Q | FELCISETRAG | Confirmed FDA, Wikidata |
| Wikidata | Q27088952 | td-8954 | Confirmed FDA, Wikidata |
| DrugBank | DB12725 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.